-
Product Name
Anti-VEGF / VEGFA / VEGF165 antibody
- Documents
-
Description
Rabbit polyclonal to VEGF / VEGFA / VEGF165
-
Tested applications
WB, IP
-
Species reactivity
human VEGFA
-
Alternative names
MGC70609 antibody; MVCD1 antibody; RP1-261G23.1 antibody; VEGF antibody; VEGF-A antibody; VPF antibody; VPF antibody; VEGF antibody; MVCD1 antibody; Vpf antibody; Vegf antibody
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with A synthetic peptide corresponding to the center region of the human VEGFA , and purified by antigen affinity chromatography.
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
WB: 5-10 μg/ml
IP: 1-4 μg/mg of lysate
-
Validations
VEGFA Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot
VEGFA Antibody, Rabbit PAb, Antigen Affinity Purified, Immunoprecipitation
-
Background
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.
-
References
- Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
- Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
- Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
- Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
- Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
- Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"